Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Moderate Buy” from Brokerages

by · The Markets Daily

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $133.00.

Several equities analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Guggenheim reissued a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd.

Check Out Our Latest Stock Report on ORKA

Insider Transactions at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the transaction, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 124,004 shares of company stock valued at $11,606,239 in the last 90 days. 23.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the company. Sei Investments Co. raised its holdings in Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after buying an additional 13,164 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Oruka Therapeutics during the first quarter valued at about $5,543,000. Handelsbanken Fonder AB acquired a new position in shares of Oruka Therapeutics during the second quarter valued at about $15,313,000. The Manufacturers Life Insurance Company grew its holdings in shares of Oruka Therapeutics by 18.3% during the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after buying an additional 11,205 shares during the last quarter. Finally, Braidwell LP bought a new stake in shares of Oruka Therapeutics during the second quarter worth about $26,473,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Trading Down 2.8%

Shares of ORKA opened at $94.96 on Friday. The stock has a market capitalization of $6.29 billion, a P/E ratio of -46.78 and a beta of -0.34. The firm’s fifty day simple moving average is $96.40 and its two-hundred day simple moving average is $73.79. Oruka Therapeutics has a 12 month low of $14.89 and a 12 month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.

See Also